• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    MapLight Therapeutics to Participate in Upcoming Investor Conferences

    3/2/26 7:00:00 AM ET
    $MPLT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MPLT alert in real time by email

    SAN FRANCISCO and BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (NASDAQ:MPLT) today announced that members of its management team will participate in the following investor conferences:

    Event: Jefferies 2026 Biotech on the Beach Summit (Miami, FL)

    Date: Tuesday, March 10th

    Format: Hosting 1x1 meetings

    Event: Leerink 2026 Global Healthcare Conference (Miami, FL)

    Date: Wednesday, March 11th

    Format: Presenting and hosting 1x1 meetings

    Event: Stifel 2026 Virtual CNS Forum

    Date: Wednesday, March 18th

    Format: Presenting and hosting 1x1 meetings

    Where available, access to the live webcasts of these events, as well as archived recordings, will be posted under the "Events & Presentations" page on the Investor section of the company's website at https://ir.maplightrx.com/news-events/events-presentations.

    About MapLight Therapeutics

    MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders. The company was founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The company's discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. 

    For more information, please visit www.maplightrx.com.

    For investor inquiries: [email protected]

    For media inquiries: [email protected]



    Primary Logo

    Get the next $MPLT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MPLT

    DatePrice TargetRatingAnalyst
    4/8/2026$37.00Buy
    Needham
    4/7/2026Buy
    TD Cowen
    3/19/2026$35.00Buy
    Canaccord Genuity
    11/21/2025$34.00Overweight
    Morgan Stanley
    11/21/2025$28.00Buy
    Stifel
    11/21/2025$32.00Buy
    Jefferies
    11/21/2025$30.00Outperform
    Leerink Partners
    More analyst ratings

    $MPLT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Malenka Robert C. sold $260,398 worth of Voting Common Stock (14,195 units at $18.34), decreasing direct ownership by 4% to 325,059 units (SEC Form 4)

    4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)

    2/24/26 6:57:12 PM ET
    $MPLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Pavlov George bought $441,168 worth of Voting Common Stock (25,000 units at $17.65) (SEC Form 4)

    4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)

    2/20/26 6:25:04 PM ET
    $MPLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Malenka Robert C. sold $220,632 worth of Voting Common Stock (12,116 units at $18.21), decreasing direct ownership by 3% to 339,254 units (SEC Form 4)

    4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)

    2/18/26 7:33:37 PM ET
    $MPLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MPLT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Pavlov George bought $441,168 worth of Voting Common Stock (25,000 units at $17.65) (SEC Form 4)

    4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)

    2/20/26 6:25:04 PM ET
    $MPLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Garnett Timothy John bought $252,678 worth of Voting Common Stock (14,124 units at $17.89) (SEC Form 4)

    4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)

    2/12/26 5:45:08 PM ET
    $MPLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Novo Holdings A/S converted options into 2,733,681 units of Voting Common Stock and bought $16,199,997 worth of Voting Common Stock (952,941 units at $17.00) (SEC Form 4)

    4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)

    10/30/25 4:31:43 PM ET
    $MPLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MPLT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected to reach target enrollment (n=300) in April 2026, with topline results expected in the third quarter of 2026Phase 2 IRIS trial for ML-004 for autism spectrum disorder has completed enrollment, with topline results expected in the third quarter of 2026Received FDA Fast Track designation for ML-007C-MA for Alzheimer's disease psychosis; topline results from Phase 2 VISTA trial expected in the second half of 2027Expanded pipeline with a next-generation M1/M4 muscarinic agonist program, ML-055, with candidate nomination expected in 2026Ended the year with $453.1 million in cash, cash equivalents and investments, which is expected to f

    3/26/26 7:00:00 AM ET
    $MPLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MapLight Therapeutics to Participate in Upcoming Investor Conferences

    SAN FRANCISCO and BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (NASDAQ:MPLT) today announced that members of its management team will participate in the following investor conferences: Event: Jefferies 2026 Biotech on the Beach Summit (Miami, FL)Date: Tuesday, March 10thFormat: Hosting 1x1 meetings Event: Leerink 2026 Global Healthcare Conference (Miami, FL)Date: Wednesday, March 11thFormat: Presenting and hosting 1x1 meetings Event: Stifel 2026 Virtual CNS ForumDate: Wednesday, March 18thFormat: Presenting and hosting 1x1 meetings Where available, access to the live webcasts of these events, as well as archived recordings, will be posted under the "Events & P

    3/2/26 7:00:00 AM ET
    $MPLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026

    SAN FRANCISCO and BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (MapLight) (NASDAQ:MPLT) today announced an update to the expected timing of topline results for its ongoing Phase 2 ZEPHYR and IRIS clinical studies, which are progressing ahead of schedule. The company's Phase 2 ZEPHYR trial evaluating ML-007C-MA for the treatment of schizophrenia continues to enroll robustly, and topline results are now expected in the third quarter of 2026. The ZEPHYR study is a randomized, double-blind, placebo-controlled trial that is expected to enroll 300 hospitalized adult participants with schizophrenia experiencing acute exacerbation of psychosis. "The accelerated enrollmen

    1/9/26 7:00:00 AM ET
    $MPLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MPLT
    SEC Filings

    View All

    SEC Form S-8 filed by MapLight Therapeutics Inc.

    S-8 - MapLight Therapeutics, Inc. (0001770069) (Filer)

    3/26/26 7:54:48 AM ET
    $MPLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by MapLight Therapeutics Inc.

    10-K - MapLight Therapeutics, Inc. (0001770069) (Filer)

    3/26/26 7:20:23 AM ET
    $MPLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MapLight Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - MapLight Therapeutics, Inc. (0001770069) (Filer)

    3/26/26 7:10:11 AM ET
    $MPLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MPLT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham initiated coverage on MapLight Therapeutics with a new price target

    Needham initiated coverage of MapLight Therapeutics with a rating of Buy and set a new price target of $37.00

    4/8/26 8:37:23 AM ET
    $MPLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen initiated coverage on MapLight Therapeutics

    TD Cowen initiated coverage of MapLight Therapeutics with a rating of Buy

    4/7/26 8:47:13 AM ET
    $MPLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Canaccord Genuity initiated coverage on MapLight Therapeutics with a new price target

    Canaccord Genuity initiated coverage of MapLight Therapeutics with a rating of Buy and set a new price target of $35.00

    3/19/26 8:26:25 AM ET
    $MPLT
    Biotechnology: Pharmaceutical Preparations
    Health Care